Daxor to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House

New York, NY, April 4, 2018

Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces it will present at 3:00pm on Monday, April 9th at this year’s MicroCap Conference and will be available for meetings with investors on both April 9th and 10th.

Michael Feldschuh, CEO of Daxor stated, “We are looking forward to participating in the MicroCap Conference for the first time. It will provide us an opportunity to present Daxor’s unique technology and significant market potential to investors.”

The MicroCap Conference is an event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with the management of small, innovative companies, learn from expert panels, and meet other microcap investors.  The MicroCap Conference will take place in New York City at the Essex House on April 9th and 10th. Registration will begin on Monday at 7:00AM and will last until the evening. Both days of the conference will be occupied with company presentations, 1-on-1 meetings, roundtables, expert panel discussions, and networking.

Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:
Daxor Corporation: Soren Thompson 212-330-8502 (Investor Relations) sthompson@daxor.com